Merck - 52 Year Stock Split History | MRK

Stock split history for Merck since 1970. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Merck Annual Stock Splits
Merck Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $232.903B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $461.811B 17.76
Pfizer (PFE) United States $282.789B 9.86
Eli Lilly (LLY) United States $280.478B 33.09
AbbVie (ABBV) United States $269.361B 11.81
Novartis AG (NVS) Switzerland $196.117B 14.12
GlaxoSmithKline (GSK) United Kingdom $110.899B 12.95
Novo Nordisk (NVO) Denmark $0.000B 30.80